Eagle Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun '23 Jun 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Revenue	257.55	316.61	171.55	187.8	195.89	213.31
Revenue Growth (YoY)	-5.38%	84.56%	-8.66%	-4.13%	-8.17%	-9.88%
Cost of Revenue	77.68	94.94	42.18	45.47	60.9	61.92
Gross Profit	179.88	221.67	129.37	142.34	135	151.4
Selling, General & Admin	102.52	87.13	75.32	78.6	76.37	60.51
Research & Development	35.65	34.09	51.28	30.79	36.81	44.42
Operating Expenses	138.17	121.21	126.6	109.38	113.18	104.93
Operating Income	41.71	100.46	2.77	32.95	21.82	46.47
Interest Expense	-6.09	-4.05	-1.64	-2.58	-2.69	-2.74
Interest & Investment Income	0.28	0.27	0.56	0.56	2.17	0.16
Other Non Operating Income (Expenses)	-3.61	-10.33	-0.76	-	0.7	-
EBT Excluding Unusual Items	32.29	86.35	0.94	30.94	22	43.89
Merger & Restructuring Charges	-1.3	-12.6	-	-	-	-10.62
Gain (Loss) on Sale of Investments	-2.42	-5.42	-5.48	-8.26	-	-
Other Unusual Items	0.6	-6.9	-	-	-	0.76
Pretax Income	29.17	61.43	-4.55	22.68	22	34.04
Income Tax Expense	17.22	25.79	4.08	10.69	7.69	2.14
Net Income	11.95	35.64	-8.63	11.99	14.31	31.9
Net Income to Common	11.95	35.64	-8.63	11.99	14.31	31.9
Net Income Growth	-47.57%	-	-	-16.24%	-55.14%	-38.58%
Shares Outstanding (Basic)	13	13	13	13	14	15
Shares Outstanding (Diluted)	13	13	13	14	14	15
Shares Change (YoY)	2.21%	0.11%	-5.23%	-2.60%	-7.46%	-3.96%
EPS (Basic)	0.91	2.76	-0.66	0.89	1.04	2.16
EPS (Diluted)	0.91	2.73	-0.66	0.87	1.01	2.09
EPS Growth	-48.44%	-	-	-13.86%	-51.68%	-36.09%
Free Cash Flow	-9.39	50.52	27.9	48.75	55.21	52.25
Free Cash Flow Per Share	-0.71	3.87	2.14	3.54	3.90	3.42
Gross Margin	69.84%	70.02%	75.41%	75.79%	68.91%	70.97%
Operating Margin	16.19%	31.73%	1.61%	17.55%	11.14%	21.78%
Profit Margin	4.64%	11.26%	-5.03%	6.38%	7.31%	14.96%
Free Cash Flow Margin	-3.65%	15.96%	16.26%	25.96%	28.18%	24.50%
EBITDA	62.33	112.48	6.53	36.49	25.31	50.14
EBITDA Margin	24.20%	35.53%	3.81%	19.43%	12.92%	23.51%
D&A For EBITDA	20.62	12.02	3.76	3.54	3.49	3.67
EBIT	41.71	100.46	2.77	32.95	21.82	46.47
EBIT Margin	16.19%	31.73%	1.61%	17.55%	11.14%	21.78%
Effective Tax Rate	59.04%	41.98%	-	47.13%	34.94%	6.27%
Revenue as Reported	257.55	316.61	171.55	187.8	195.89	213.31

Updated Aug 8, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.